CRNX, Jefferies and Crinetics Pharmaceuticals

Jefferies Upgrades Crinetics Pharmaceuticals (CRNX)
Fintel reports that on January 22, 2025, Jefferies upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from Hold to Buy. Analyst Price Forecast Suggests 94.74% Upside As of December 23,
Crinetics upgraded to Buy from Hold at Jefferies
Jefferies analyst Dennis Ding upgraded Crinetics (CRNX) to Buy from Hold with an unchanged price target of $55. The firm cites the pullback in
Crinetics Pharmaceuticals (NASDAQ:CRNX) Earns “Buy” Rating from HC Wainwright
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $81.
Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against other Billionaire Joseph Edelman’s long-term stock picks.
How Does Crinetics Pharmaceuticals Inc (CRNX) Stack Up Against Its Industry Peers?
Crinetics Pharmaceuticals Inc (CRNX) stock saw a decline, ending the day at $40.59 which represents a decrease of $-7.91 or -16.31% from the prior close of $48.5. The stock opened at $46.64 and touched a low of $40.
Piper Sandler Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report),
Crinetics upgraded to buy by Jefferies, atumelnant potential cited
Jefferies has upgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant in the treatment of congenital adrenal hyperplasia,
news.stocktradersdaily14d
Trading (CRNX) With Integrated Risk Controls
GET MORE AI-GENERATED SIGNALS: January 08, 2025, 09:36 am ET, BY Simon M.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...
Seeking Alpha12d
Crinetics falls after mid-stage trial data adrenal disorder therapy
Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) traded sharply lower after the company posted initial data from a Phase 2 trial for atumelnant, its experimental therapy for congenital adrenal ...
Yahoo Finance16d
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will ...
Nasdaq6y
Crinetics Pharmaceuticals, Inc. Common Stock (CRNX) Earnings
Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...